Tiger Brokers

AstraZeneca Results Should Allay Investor Fears

Dow Jones
Jul 27

0713 GMT - AstraZeneca's solid results should allay investor fears about the U.K. drugmaker's long-term targets, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The company reiterated its guidance for this year and its 2030 target despite the failure of a clinical trial for its Wainua drug earlier this month, the analysts say. AstraZeneca also said experimental treatment sonesitatug vedotin showed positive overall-survival results--but not on survival without the disease getting worse--in a late-stage study for gastric cancers, which should contribute to ease some fears about its pipeline strength and ability to innovate, they add. Shares rise 1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 27, 2026 03:13 ET (07:13 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10